CBUS — Cibus, Inc.

Cibus, Inc. Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Cash and Cash Equivalents: As of December 31, 2025, Cibus reported $9.9 million in cash. A public offering in January 2026 raised $22.3 million, extending the company's financial runway.
• Net Loss: The company recorded a net loss of $31.9 million for Q4 2025, compared to a loss of $25.8 million in Q4 2024.
• Operating Expenses: R&D expenses decreased to $9.4 million from $12.4 million year-over-year, while SG&A expenses fell to $5.1 million from $6.8 million, reflecting cost-saving initiatives.
• Royalty Liability Interest Expense: Increased to $9.4 million from $8.2 million year-over-year due to interest recognition on royalty liabilities.

2. Strategic Updates and Business Highlights

• Customer Engagement: Cibus has secured seven rice customers, representing a potential annual royalty opportunity of over $200 million. The company is focusing on deeper integration with seed companies for ongoing genomic editing relationships.
• Regulatory Progress: Significant advancements in gene editing regulations were noted, particularly with the EU's new genomic techniques legislation, which opens up a 100 million-acre market. Cibus has also received positive regulatory determinations in the U.S. and Latin America.
• RISE Program: The RISE program is on track for market entry in Latin America by 2027, with plans for U.S. expansion in 2028 and entry into India and Asia by 2030.
• Technological Advancements: Cibus reported improved editing efficiency and scalability through AI and automation, enhancing its ability to serve as a gene editing engine for partners.

3. Forward Guidance and Outlook

• Revenue Generation: Cibus aims to generate substantial revenue from its RISE program and sustainable ingredients, with initial commercial launches expected in Latin America in 2027.
• Operational Focus: The company plans to maintain a disciplined approach to capital allocation, targeting a reduction in annual net cash usage to approximately $30 million or less in 2026.
• Market Expansion: Cibus is exploring opportunities in Brazil and Argentina, with significant growth potential in India anticipated towards the end of the decade.

4. Bad News, Challenges, or Points of Concern

• Net Loss Increase: The increase in net loss year-over-year raises concerns about the company's ability to achieve profitability in the near term.
• Revenue Timing: Some revenue recognition was delayed, which may affect short-term financial performance and investor sentiment.
• Regulatory Risks: While recent regulatory developments are favorable, any future changes in regulations could impact the company's growth trajectory and market access.

5. Notable Q&A Insights

• EU Regulatory Impact: Management emphasized the importance of the EU regulatory framework, which could influence capital expenditures for canola and other crops.
• Commercialization Steps: The company outlined the steps to commercialization in Latin America, focusing on chemical registration and trait work to prepare for the 2027 launch.
• Acreage Growth: Cibus targets 5 to 7 million acres in the Americas initially, with potential expansion into India representing an additional 120 million acres by 2030.
• Gene Edits as a Service: There is growing interest in offering gene editing as a service, with favorable negotiations anticipated due to the speed and efficiency of Cibus's technology.

Overall, Cibus, Inc. is positioned for growth in the gene editing sector, with significant opportunities in rice and sustainable ingredients, despite facing challenges related to financial losses and the timing of revenue recognition.